Literature DB >> 18202925

Bisphosphonate treatment and radiotherapy in metastatic breast cancer.

A Ugur Ural1, Ferit Avcu, Yusuf Baran.   

Abstract

Patients with advanced breast cancer frequently develop metastasis to bone. Bone metastasis results in intractable pain and high risk of pathologic fractures due to osteolysis. The treatment of breast cancer patients with bone metastases requires a multidisciplinary approach. Radiotherapy is an established treatment for metastatic bone pain. It may be delivered either as a localized low dose treatment for localized bone pain or systemically for more widespread symptoms. Bisphosphonates have been shown to reduce morbidity and bone pain from bone metastases when given to patients with metastatic bone disease. In vivo studies indicate that early bisphosphonates administration in combination with radiotherapy improves remineralization and restabilization of osteolytic bone metastases in animal tumor models. This review focused on a brief discussion about biology of bone metastases, the effects of radiotherapy and bisphosphonate therapy, and possible mechanisms of combination therapy in metastatic breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18202925     DOI: 10.1007/s12032-008-9044-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  47 in total

1.  Cellular responses to ionizing radiation damage.

Authors:  L Li; M Story; R J Legerski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-15       Impact factor: 7.038

2.  Bisphosphonates may potentiate radiation effects: a new approach in cancer treatment?

Authors:  A Ugur Ural; Ferit Avcu
Journal:  Biochem Biophys Res Commun       Date:  2005-10-21       Impact factor: 3.575

3.  Bisphosphonates as anticancer drugs.

Authors:  G R Mundy; T Yoneda
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

4.  Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines.

Authors:  Ece Algur; Roger M Macklis; Urs O Häfeli
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

5.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

Review 6.  The evolution of the conservative approach to breast cancer.

Authors:  Alberto Luini; Giovanna Gatti; Stefano Zurrida; Nina Talakhadze; Fabricio Brenelli; Daniela Gilardi; Giovanni Paganelli; Roberto Orecchia; Enrico Cassano; Giuseppe Viale; Claudia Sangalli; Bettina Ballardini; Gabriela Rosali dos Santos; Umberto Veronesi
Journal:  Breast       Date:  2007-04       Impact factor: 4.380

7.  Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model.

Authors:  Robert Krempien; Peter E Huber; Wolfgang Harms; Martina Treiber; Michael Wannenmacher; Burkhardt Krempien
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

8.  Anti-myeloma activity of pamidronate in vivo.

Authors:  M V Dhodapkar; J Singh; J Mehta; A Fassas; K R Desikan; M Perlman; N C Munshi; B Barlogie
Journal:  Br J Haematol       Date:  1998-11       Impact factor: 6.998

9.  The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

Authors:  S P Jagdev; R E Coleman; C M Shipman; A Rostami-H; P I Croucher
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

10.  Evolving therapeutic role of bisphosphonates in multiple myeloma.

Authors:  A U Ural; F Avcu
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

View more
  5 in total

Review 1.  Symptom management in metastatic breast cancer.

Authors:  William Irvin; Hyman B Muss; Deborah K Mayer
Journal:  Oncologist       Date:  2011-08-31

2.  Effects of zoledronate on the radiation-induced collagen breakdown: a prospective randomized clinical trial.

Authors:  M Gierloff; M Reutemann; A Gülses; P Niehoff; J Wiltfang; Y Açil
Journal:  Clin Transl Oncol       Date:  2014-11-26       Impact factor: 3.405

Review 3.  Optimal management of bone metastases in breast cancer patients.

Authors:  Mh Wong; N Pavlakis
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-05-02

4.  Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis.

Authors:  Robert Foerster; Christian Eisele; Thomas Bruckner; Tilman Bostel; Ingmar Schlampp; Robert Wolf; Juergen Debus; Harald Rief
Journal:  Radiat Oncol       Date:  2015-03-07       Impact factor: 3.481

5.  FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.

Authors:  Peter A Fasching; Sebastian M Jud; Maik Hauschild; Sherko Kümmel; Martin Schütte; Matthias Warm; Volker Hanf; Dieter Grab; Jutta Krocker; Elmar Stickeler; Rolf Kreienberg; Thomas Müller; Thorsten Kühn; Christopher Wolf; Steffen Kahlert; Stefan Paepke; Michael Berghorn; Mathias Muth; Monika Baier; Birgit Wackwitz; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Michael P Lux
Journal:  BMC Cancer       Date:  2014-02-05       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.